AIMT Quote, Trading Chart, Aimmune Therapeutics Inc.

$ Last:

Change Percent:

$ Open:

$ Previous Close:

$ High:

$ Low:

0 Volume:

12/31/1969 04:00:00 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2019-12-05	29.48	29.13	29.63	28.92	424,778
2019-12-04	28.77	29.40	29.50	28.605	698,594
2019-12-03	27.69	28.59	28.71	27.6381	586,167
2019-12-02	28.01	27.89	28.10	27.35	782,892
2019-11-29	27.98	27.92	28.14	27.8247	286,233
2019-11-28	27.42	27.99	28.22	27.38	586,115
2019-11-27	27.42	27.99	28.22	27.38	586,115
2019-11-26	27.75	27.37	28.00	27.26	389,179
2019-11-25	27.75	27.81	28.05	26.98	801,769
2019-11-22	26.74	27.51	27.545	26.35	501,584
2019-11-21	25.81	26.48	26.62	25.26	1,066,900
2019-11-20	27.23	25.77	27.25	25.65	1,675,606
2019-11-19	27.07	27.40	27.70	27.00	876,892
2019-11-18	27.06	26.95	27.23	26.38	557,509
2019-11-15	27.09	26.67	27.09	26.46	568,819
2019-11-14	27.42	26.83	27.68	26.6401	602,497
2019-11-13	28.24	27.57	28.24	27.20	870,387
2019-11-12	28.73	28.32	29.28	28.17	456,707
2019-11-11	28.98	28.82	29.50	28.5175	497,613
2019-11-08	28.50	29.48	29.68	28.34	626,668

Stock Information

Aimmune Therapeutics Inc. Company Name:

AIMT Stock Symbol:

NASDAQ Market:

Get AIMT Alerts

News, Short Squeeze, Breakout and More Instantly...

NEXT ALERT COUNTDOWN

RECENT AIMT NEWS

AIMT - AIMT Remains Undervalued Before FDA Decision On Palforzia

Aimmune Therapeutics, Inc. ( AIMT ) has risen more than 80% since early September (from under $20 to near $34 now) in anticipation of the FDA approval of Palfrozia – previously known as AR-101 – as the first ever approved treatment for children who suffer from peanut allergies. B...
AIMT - The Cutting Edge Of Systematic Investing

Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
AIMT - Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Aimmune Therapeutics ' (NASDAQ: AIMT) share price has gained 11% over the past month as the company waits for the Food and Drug Administration to issue an approval decision on its very first drug, one that represents the theme of its three-drug pipeline: treatments to address food allerg...